23 September 2019 - For treatment of diffuse intrinsic pontine glioma, a difficult to treat form of childhood brain tumour.
Mateon Therapeutics announced today that the US FDA granted rare paediatric disease designation for OT101/Trabedersen for the treatment of diffuse intrinsic pontine glioma as a drug for a “rare paediatric disease.”
OT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2.